Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-06-13-Speech-3-215"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20010613.7.3-215"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
". – Mr President, during the LDC Conference I met with the new administrator of US Aid, and I can tell Mr Howitt that the issues he was looking at largely mirrored those I have mentioned today namely prevention of HIV/AIDS – the real problem being delivery – and so on.
That was more promising than many other things we hear from his government. It remains to be seen whether the announced contribution of USD 200 million from the US Government to this fund is approved by Congress, and whether it will in fact be additional money, but that does not form part of our more restricted deliberations here.
It is useful to pursue the dialogue with the United States on these issues, especially where we could feasibly agree on a practical approach, so I will continue working in this vein.
As to the second question on using the national emergencies clause as a basis for opening up for some of the elements in the TRIPS Agreement, have been sending a clear signal to our partners in the developing world that the Commission is interested in supporting their efforts to find and use the most flexible interpretation of the Agreement and we have also stated – as we did at a joint meeting with the CEOs of the major pharmaceutical companies that Pascal Lamy and myself attended – that we see a need to check the existing agreement, so as to ensure that the interpretation is good enough to facilitate better use of these possibilities in developing countries. However, we have not pinpointed any specific cases on which we can focus and act in a concrete manner. That said, we have expressed a strong desire to do so.
What we have done is to apply pressure by announcing a total untying with regard to all essential drugs used to treat these transmittable diseases. Opening up not only regionally, but also globally, should make price differentiation more difficult. It should also make for a change in stance from bidders from around the world and from the generic drug producers."@en1
|
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples